Cardiovascular complications of immunosuppressive agents in renal transplant recipients

Bibliographys

• GRUNDY SM, HANSEN B, SMITH SC Jr et al.: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler. Thromb. Vase. Biol. (2004) 24:e19–e24.
   Google Scholar
• CARR MC, BRUNZELL JD: Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metab. (2004) 89:2601–2607.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM: Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. (2004) 89:2595–2600.
   PubMed Web of Science ®Google Scholar
• NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 108:1772–1778.
   PubMed Web of Science ®Google Scholar
• BARRY JM: Current status of renal transplantation. Patient evaluations and outcomes. Urol. Clin. North Am. (2001) 28:677–686.
   PubMed Web of Science ®Google Scholar
• FISCHEREDER M, KRETZLER M: New immunosuppressive strategies in renal transplant recipients. J. Nephro/. (2004) 17:9–18.
   PubMed Web of Science ®Google Scholar
• BRAUN WE: Update on kidney transplantation: increasing clinical success, expanding waiting lists. Cleve. Clin. J. Med. (2002) 69:501–504.
   PubMed Web of Science ®Google Scholar
• NAF S, JOSE RM, RECASENS M, ASTUDILLO E, FERNANDEZ-CRUZ L, ESMATJES E: Macrovascular events after kidney-pancreas transplantation in Type 1 diabetic patients. Transplant. Proc. (2003) 35:2019–2020.
   PubMed Web of Science ®Google Scholar
• DIAZ JM, SAINZ Z, GUIRADO LL et al.:Risk factors for cardiovascular disease after renal transplantation. Transplant. Proc. (2003) 35:1722–1724.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-FRESNEDO G, ESCALLADA R, DE FRANCISCO AL et al.: Posttransplant diabetes is a cardiovascular risk factor in renal transplant patients. Transplant. Proc. (2003) 35:700.
   Google Scholar
• RICE M, MARTIN J, HATHAWAY D, TOLLEY E: Prevalence of cardiovascular risk factors before kidney transplantation. Prog. Transplant. (2002) 12:299–304.
   PubMedGoogle Scholar
• BOUCHER A, MASSE M, LAUZON L, MORIN M, DANDAVINO R: Impact of immunosuppressive regimen on cardiovascular risk factors in kidney transplant recipients. Transplant. Proc. (2002) 34:1799–1802.
   PubMed Web of Science ®Google Scholar
• HYPOLITE 10, BUCCI J, HSHIEH P et al.: Acute coronary syndromes after renal transplantation in patients with end-stage renal disease resulting from diabetes. Am. J. Transplant. (2002) 2:274–281.
   Google Scholar
• FERNANDEZ-FRESNEDO G, ESCALLADA R, RODRIGO E et al.: The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation (2002) 73:1345–1348.
   PubMed Web of Science ®Google Scholar
• MARCEN R, MORALES JM, FERNANDEZ-JUAREZ G et al.: Risk factors of ischemic heart disease after renal transplantation. Transplant. Proc. (2002) 34:394–395.
   PubMed Web of Science ®Google Scholar
• ROGERS CC, ALLOWAY RR, BOARDMAN RE et al.: Global Cardiovascular risk ynder early steroid cessation decrease progressively in the first year posttransplant. Am. J. Transplant. (2004) Abstract 513.
   Google Scholar
• RIGATTO C: Clinical epidemiology of cardiac disease in renal transplant recipients. Semin. Dial. (2003) 16:106–110.
   PubMed Web of Science ®Google Scholar
• RIGATTO C, PARFREY P: Factors governing cardiovascular risk in the patient with a failing renal transplant. Pent. Dial. Int. (2001) 21\(Suppl. 3):S275–S279.
   Google Scholar
• PARFREY PS, FOLEY RN, RIGATTO C: Risk issues in renal transplantation: cardiac aspects. Transplant. Proc. (1999) 31:291–293.
   PubMed Web of Science ®Google Scholar
• AKER S, IVENS K, GRABENSEE B, HEERING P: Cardiovascular risk factors and diseases after renal transplantation. Int. Urol. Nephrol. (1998) 30:777–788.
   PubMedGoogle Scholar
• HUMAR A, KERR SR, RAMCHARAN T, GILLINGHAM KJ, MATAS AJ: Pen-operative cardiac morbidity in kidney transplant recipients: incidence and risk factors. Clin. Transplant. (2001) 15:154–158.
   PubMed Web of Science ®Google Scholar
• •Describe early risk of MI and impact of early MI on graft and patient survivals.
   Google Scholar
• PRATHERJC, GOLCONDA MS, OLYAEI AJet a/. : Cardiovascular risk factor profile in women recipients of renal transplant: Abstract 718. American Society of Transplantation meeting, Boston (2004).
   Google Scholar
• KIBERD B, KEOUGH-RYAN T, PANEK R: Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am. J. Transplant. (2003) 3:1393–1399.
   PubMed Web of Science ®Google Scholar
• PESCHKE B, SCHEUERMANN EH, GEIGER H, BOLSCHER S, KACHEL HG, LENZ T: Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin. Nephrol. (1999) 51:290–295.
   PubMed Web of Science ®Google Scholar
• OPELZ G, WUJCIAK T, RITZ E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. (1998) 53:217–222.
   PubMed Web of Science ®Google Scholar
• KASISKE BL, ANJUM S, SHAH R et al.: Hypertension after kidney transplantation. Am. J. Kidney Dis. (2004) 43:1071–1081.
   PubMed Web of Science ®Google Scholar
• •Focusing on prevalence, treatment, control and clinical correlates of hypertension and its association with outcomes.
   Google Scholar
• CHOBANIAN AV BAKRIS GL, BLACK HR et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 289:2560–2572.
   Google Scholar
• ••Expert consensus on the treatment of hypertension.
   Google Scholar
• WEIR MR: Blood pressure management in the kidney transplant recipient. Adv. Chronic Kidney Dis. (2004) 11:172–183.
   PubMed Web of Science ®Google Scholar
• OLYAEI AJ, DE MATTOS AM, BENNETT WM: Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr. Opin. Crit. Care (2001) 7:384–389.
   PubMedGoogle Scholar
• OLYAEI AJ, DEMATTOS AM, BENNETT WM: A practical guide to the management of hypertension in renal transplant recipients. Drugs (1999) 58:1011–1027.
   PubMed Web of Science ®Google Scholar
• OZDEMIR FN, GUZ G, SEZER S, ARAT Z, HABERAL M: Ambulatory blood pressure monitoring in potential renal transplant donors. Nephrol. Dial. Transplant. (2000) 15:1038–1040.
   PubMed Web of Science ®Google Scholar
• HRICIK DE, KNAUSS TC, BODZIAK KA et al.: Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation (2003) 76:938–942.
   PubMed Web of Science ®Google Scholar
• BOOTS JM, CHRISTIAANS MH, VAN DUIJNHOVEN EM, VAN SUYLEN RJ, VAN HOOFF JP: Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation (2002) 74:1703–1709.
   PubMed Web of Science ®Google Scholar
• DEMME RA: Hypertension in kidney transplant patient. Graft (2001) 4:248–255.
   Google Scholar
• JOHNSON RW, KREIS H, OBERBAUER R, BRATTSTROM C, CLAESSON K, ERIS J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation (2001) 72:777–786.
   PubMed Web of Science ®Google Scholar
• OBERBAUER R, KREIS H, JOHNSON RW et al.: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 76:364–370.
   PubMed Web of Science ®Google Scholar
• MARGREITER R, EUROPEAN TACROLIMUS versus CICLOSPORIN MICROEMULSION RENAL TRANSPLANTATION STUDY GROUP: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet (2002) 359:741–746.
   PubMed Web of Science ®Google Scholar
• KLEIN IH, ABRAHAMS A, VAN EDE T, HENE RJ, KOOMANS HA, LIGTENBERG G: Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation (2002) 73:732–736.
   PubMed Web of Science ®Google Scholar
• LIGTENBERG G, HENE RJ, BLANKESTIJN PJ, KOOMANS HA: Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J. Am. Soc. Nephrol. (2001) 12:368–373.
   PubMed Web of Science ®Google Scholar
• KAHAN BD: Two-year results of multicenter Phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant. Proc. (2003) 35:37S–51S.
   Google Scholar
• GONWA T, MENDEZ R, YANG HC et al.: Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation (2003) 75:1213–1220.
   PubMed Web of Science ®Google Scholar
• OLYAEI AJ, DE MATTOS AM, BENNETT WM: Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf (1999) 21:471–488.
   PubMed Web of Science ®Google Scholar
• KASISKE BL: Cardiovascular disease after renal transplantation. Semin. Nephrol. (2000) 20:176–187.
   PubMed Web of Science ®Google Scholar
• GILES JW, SEAR JW, FOEX P: Effect of chronic beta-blockade on pen-operative outcome in patients undergoing non-cardiac surgery: an analysis of observational and case control studies. Anaesthesia (2004) 59:574–583.
   PubMed Web of Science ®Google Scholar
• SACKNER-BERNSTEIN JD: Practical guidelines to optimize effectiveness of beta-blockade in patients postinfarction and in those with chronic heart failure. Am. J. Cardiol. (2004) 93:69B–73B.
   Google Scholar
• YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl. J. Med. (2000) 342:145–153.
   PubMed Web of Science ®Google Scholar
• SUWELACK B, KOBELT V, ERFMANN M et al.: Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl. Int. (2003) 16:313–320.
   PubMed Web of Science ®Google Scholar
• HAUSBERG M, KOSCH M, HOHAGE H et al.: Antihypertensive treatment in renal transplant patients - is there a role for ACE inhibitors? Ann. Transplant. (2001) 6:31–37.
   Google Scholar
• NORIS M, MISTER M, PEZZOTTA A et al.: ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney Int. (2003) 64:2253–2261.
   PubMed Web of Science ®Google Scholar
• GHODS AJ, OSSAREH S: Beneficial effect of enalapril on slowing the progression of chronic renal allograft dysfunction. Transplant. Proc. (2003) 35:2641–2642.
   PubMed Web of Science ®Google Scholar
• KASISKE B, COSIO FG, BETO J et aL: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am. J. Transplant. (2004) 4\(Suppl. 7):13–53.
   Google Scholar
• ••Expert consensus on the treatment ofhyperlipidaemia in transplant patients.
   Google Scholar
• EBPG EXPERT GROUP ON RENAL TRANSPLANTATION: European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia. Nephrol. Dial. Transplant. (2002) 17\(Suppl. 4):26–28.
   Google Scholar
• ••Expert consensus on the treatment ofhyperlipidaemia in transplant patients.
   Google Scholar
• BOOTH JC, JOSEPH JT, JINDAL RM: Influence of hypercholesterolemia on patient and graft survival in recipients of kidney transplants. Clin. Transplant. (2003) 17:101–107.
   PubMed Web of Science ®Google Scholar
• BORATYNSKA M, BANASIK M, WATOREK E, KLINGER M, DOROBISZ A, SZYBER P: Influence of hypercholesterolemia and acute graft rejection on chronic nephropathy development in renal transplant recipients. Transplant. Proc. (2003) 35:2209–2212.
   PubMed Web of Science ®Google Scholar
• CASTELLO IB: Hyperlipidemia: a risk factor for chronic allograft dysfunction. Kidney Int. - Suppl. (2002):73–77.
   PubMedGoogle Scholar
• FELLSTROM B: The effects of lipids on graft outcome. Transplant. Proc. (1999) 31:14S–15S.
   Google Scholar
• CARVALHO MF, SOARES V: Hyperlipidemia as a risk factor of renal allograft function impairment. Clin. Transplant. (2001) 15:48–52.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. (2004) 24:e149–e161.
   PubMed Web of Science ®Google Scholar
• ••Expert consensus on the treatment ofhyperlipidaemia in transplant patients. Focusing on lower LDL.
   Google Scholar
• GRUNDY SM, CLEEMAN JI, MERZ CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation (2004) 110:227–239.
   PubMed Web of Science ®Google Scholar
• HOLDAAS H, FELLSTROM B, JARDINE AG et al.: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet (2003) 361:2024–2031.
   PubMed Web of Science ®Google Scholar
• KOBASHIGAWA JA, KATZNELSON S,LAKS H et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl. J. Med. (1995) 333:621–627.
   Google Scholar
• WISSING KM, ABRAMOWICZ D, BROEDERS N, VEREERSTRAETEN P: Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transp/antation (2000) 70:464–472.
   PubMed Web of Science ®Google Scholar
• AGUILAR-SALINAS CA, DIAZ-POLANCO A, QUINTANA E et al.: Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am. J. Kidney Dis. (2002) 40:169–177.
   PubMed Web of Science ®Google Scholar
• RIGOTTI P, EUROPEAN TACROLIMUS/MMF TRANSPLANTATION STUDY GROUP: Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids. Transplant. Proc. (2002) 34:1797–1798.
   PubMed Web of Science ®Google Scholar
• HILBRANDS LB, DEMACKER PN, HOITSMA AJ, STALENHOEF AF, KOENE RA: The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J. Am. Soc. Nephrol. (1995) 5:2073–2081.
   PubMed Web of Science ®Google Scholar
• MATHIS AS, DAVE N, KNIPP GT, FRIEDMAN GS: Drug-related dyslipidemia after renal transplantation. Am. J. Health Syst. Pharm. (2004) 61:565–585.
   PubMed Web of Science ®Google Scholar
• PHAIR PG, POWELL HR, MCCREDIE DA: Lipid abnormalities in red blood cell and plasma phospholipids in cyclosporine-treated heart transplant recipients. Transplant. Proc. (1994) 26:3722–3726.
   PubMed Web of Science ®Google Scholar
• ISLAM MS, BARD JM, LE POGAMP P et al.: Serum lipoprotein (a) in renal transplant recipients treated with cyclosporin monotherapy compared to conventional treatment. Nephrol. Dial. Transplant. (1994) 9:332–333.
   Google Scholar
• KUSTER GM, DREXEL H, BLEISCH JA et al.: Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation (1994) 57:1479–1483.
   PubMed Web of Science ®Google Scholar
• ARTZ MA, BOOTS JM, LIGTENBERG G et al.: Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J. Am. Soc. Nephrol. (2003) 14:1880–1888.
   PubMed Web of Science ®Google Scholar
• ARTZ MA, BOOTS JM, LIGTENBERG G et al.: Randomized conversion from cyclosporine to tacrolimus in renal transplant patients: improved lipid profile and unchanged plasma homocysteine levels. Transplant. Proc. (2002) 34:1793–1794.
   PubMed Web of Science ®Google Scholar
• BAID-AGRAWAL S, DELMONICO FL, TOLKOFF-RUBIN NE et al.: Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation (2004) 77:1199–1202.
   PubMed Web of Science ®Google Scholar
• KAHAN BD: Sirolimus: a comprehensivereview. Expert Opin. Pharmacother. (2001) 2:1903–1917.
   PubMedGoogle Scholar
• MORRISETT JD, ABDEL-FATTAH G,KAHAN BD: Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant. Proc. (2003) 35:143S–150S.
   Google Scholar
• CHUEH SC, KAHAN BD: Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation (2003) 76:375–382.
   PubMed Web of Science ®Google Scholar
• BAI S, STEPKOWSKI SM, KAHAN BD, BRUNNER LJ: Metabolic interaction between cyclosporine and sirolimus. Transplantation (2004) 77:1507–1512.
   PubMed Web of Science ®Google Scholar
• GROBBEE DE, BOTS ML: Statin treatment and progression of atherosclerotic plaque burden. Drugs (2003) 63:893–911.
   PubMed Web of Science ®Google Scholar
• RAY JG: Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr. Opin. Pulm. Med. (2003) 9:378–384.
   PubMed Web of Science ®Google Scholar
• LAW MR, WALD NJ, RUDNICKA AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. J. (2003) 326:1423.
   PubMed Web of Science ®Google Scholar
• STEVERMER JJ, MEADOWS SE: What is the target for low-density lipoprotein cholesterol in patients with heart disease?" Fam. Pract. (2002) 51:893.
   Web of Science ®Google Scholar
• HEBERT PR, GAZIANO JM, CHAN KS, HENNEKENS CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA (1997) 278:313–321.
   Google Scholar
• MARON DJ, FAZIO S, LINTON MF: Current perspectives on statins. Circulation (2000) 101:207–213.
   PubMed Web of Science ®Google Scholar
• MCMILLAN K: Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Health Syst. Pharm. (1996) 53:2206–2214.
   PubMed Web of Science ®Google Scholar
• THOMPSON PD, CLARKSON P, KARAS RH: Statin-associated myopathy. JAMA (2003) 289:1681–1690.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163:553–564.
   PubMed Web of Science ®Google Scholar
• HERMAN RJ: Drug interactions and the statins. CMAJ (1999) 161:1281–1286.
   PubMed Web of Science ®Google Scholar
• VERGOULAS G, MISERLIS G, SOLONAKI F et al.: Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl. Int. (2000) 13\(Suppl. 1):564–567.
   Google Scholar
• OK E, KURSAT S, ALEV M et al.: Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients. Nephron (1996) 73:491–492.
   PubMedGoogle Scholar
• MUSCARI A, PUDDU GM, PUDDU P: Lipid-lowering drugs: are adverse effects predictable and reversible? Cardiology (2002) 97:115–121.
   PubMed Web of Science ®Google Scholar
• TONELLI M, COLLINS D, ROBINS S, BLOOMFIELD H, CURHAN GC: Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am. J. Idney Dis. (2004) 44:832–839.
   PubMed Web of Science ®Google Scholar
• ANGELES C, LANE BP, MILLER F, NORD EP: Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am. J. Kidney Dis. (2004) 44:543–550.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, LIPKA LJ, SAGER PT et al.: Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int. J. Clin. Pract. (2004) 58:653–658.
   PubMed Web of Science ®Google Scholar
• CHENG AY: Safety and tolerability of ezetimibe- reply. Can. J. Clin. Pharmacol. (2004) 11:E46.
   Google Scholar
• COSIO FG, PESAVENTO TE, KIM S, OSEI K, HENRY M, FERGUSON RM: Patient survival after renal transplantation: IV Impact of post-transplant diabetes. Kidney Int. (2002) 62:1440–1446.
   PubMed Web of Science ®Google Scholar
• EBPG EXPERT GROUP ON RENAL TRANSPLANTATION: European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.4. Cardiovascular risks. Post-transplant diabetes mellitus. Nephrol. Dial. Transplant. (2002) 17\(Suppl. 4):28.
   Google Scholar
• SALVADORI M, BERTONI E, ROSATI A, ZANAZZI M: Post-transplant diabetes mellitus. J. Nephrol. (2003) 16:626–634.
   PubMed Web of Science ®Google Scholar
• HAGEN M, HJELMESAETH J, JENSSEN T, MORKRID L, HARTMANN A: A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. Nephrol. Dial. Transplant. (2003) 18:2154–2159.
   PubMed Web of Science ®Google Scholar
• YILDIZ A, TUTUNCU Y, YAZICI H et al.: Association between hepatitis C virus infection and development of posttransplantation diabetes mellitus in renal transplant recipients. Transplantation (2002) 74:1109–1113.
   PubMed Web of Science ®Google Scholar
• BENHAMOU PY, PENFORNIS A: Natural history, prognosis, and management of transplantation-induced diabetes mellitus. Diabetes Metab. (2002) 28:166–175.
   PubMed Web of Science ®Google Scholar
• KASISKE BL, SNYDER JJ, GILBERTSON D, MATAS AJ: Diabetes mellitus after kidney transplantation in the United States. Am. J. Transplant. (2003) 3:178-185. Focusing on the incidence, risk factors and clinical relevance of post-transplant diabetes mellitus.
   Google Scholar
• COSIO FG, PESAVENTO TE, OSEI K, HENRY ML, FERGUSON RM: Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int. (2001) 59:732–737.
   PubMed Web of Science ®Google Scholar
• TAMURA K, FUJIMURA T, TSUTSUMI T et al.: Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation (1995) 59: 1606-1613.
   Google Scholar
• TAMURA K: FK506: mechanism of immunosuppression and adverse-effects. Toxica Sci. (1995) 20:477–479.
   Google Scholar
• PASCUAL J, MARCEN R, BURGOS FJ et al.: A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe. Transplant. Proc. (2003) 35:1760–1761.
   PubMed Web of Science ®Google Scholar
• RABKIN JM, CORLESS CL, ROSEN HR, OLYAEI AJ: Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am. J. Surg-. (2002) 183:595–599.
   PubMed Web of Science ®Google Scholar
• WEIR MR, FINK JC: Risk for posttransplant diabetes mellitus with current immunosuppressive medications. Am. J. Kidney Dis. (1999) 34:1–13.
   PubMed Web of Science ®Google Scholar
• FABREGA AJ, MESLAR P, COHAN J, LASH J, POLLAK R: Long-term (24-month) follow-up of steroid withdrawal in renal allograft recipients with posttransplant diabetes mellitus. Transp/antation (1995) 60: 1612-1614.
   Google Scholar
• SAKHUJA V SHARMA UK, JHA V, MINZ M, CHUGH KS: High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression. Transplant. Proc. (1995) 27:2728–2730.
   PubMed Web of Science ®Google Scholar
• TORNATORE KM, BIOCEVICH DM, REED KA et al.: Post-transplant diabetes mellitus and methylprednisolone pharmacokinetics in African-American and Caucasian renal transplant recipients. Clin. Transplant. (1995) 9:289–296.
   PubMed Web of Science ®Google Scholar
• FRANZ MJ: Prioritizing diabetes nutrition recommendations based on evidence. Minerva Med. (2004) 95:115–123.
   PubMedGoogle Scholar
• PRICE CP: Point-of-care testing in diabetes mellitus. Clin. Chem. Lab. Med. (2003) 41:1213–1219.
   PubMed Web of Science ®Google Scholar
• MARKELL M: Clinical impact of posttransplant diabetes mellitus. Transplant. Proc. (2001) 33:19S–22S.
   Google Scholar
• BOHANNON N: Insulin therapy for reducing cardiovascular risk in patients with Type 2 diabetes. Clin. Cornerstone (2003) Suppl. 4:S21–S27.
   Google Scholar
• HERMANS MP, BUYSSCHAERT M: Pharmacological treatment of Type 2 diabetes. Acta Clin. Belg. (2004) 59:59–66.
   PubMed Web of Science ®Google Scholar
• BELL DS: Type 2 diabetes mellitus: what is the optimal treatment regimen? Am. J. Med. (2004) 116(Suppl. 5A):23S–29S.
   Google Scholar
• FONSECA V: Clinical significance of targeting postprandial and fasting hyperglycemia in managing Type 2 diabetes mellitus. Curr. Med. Res. Opin. (2003) 19:635–641.
   PubMed Web of Science ®Google Scholar
• MANRIQUE J, ERRASTI P, LAVILLA J et aL: Treatment of hyperhomocysteinemia after renal transplantation. Transplant. Proc. (2003) 35:1742–1744.
   PubMed Web of Science ®Google Scholar
• EBPG EXPERT GROUP ON RENAL TRANSPLANTATION: European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.5.5. Cardiovascular risks. Hyperhomocysteinaemia. Nephrol. Dial. Transplant. (2002) 17\(Suppl. 4):28–29.
   Google Scholar
• FRIEDMAN AN, ROSENBERG IH, SELHUB J, LEVEY AS, BOSTOM AG: Hyperhomocysteinemia in renal transplant recipients. Am. J. Transplant. (2002) 2:308–313.
   PubMed Web of Science ®Google Scholar
• DUCLOUX D, KAZORY A, CHALOPIN JM: Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. (2004) 66:441–446.
   PubMed Web of Science ®Google Scholar
• LAURES AS, GOMEZ E, ALVAREZ V, COTO E, BALTAR J, ALVAREZ-GRANDE J: Influence of anticalcineurinic therapy in plasma homocysteine levels of renal transplant recipients: a prospective study. Transplant. Proc. (2003) 35:1739–1741.
   PubMed Web of Science ®Google Scholar
• SAVAJ S, REZAKHANI S, POROOSHANI F, GHODS AJ: Effect of folic acid therapy on serum homocysteine level in renal transplant recipients. Transplant. Proc. (2002) 34:2419.
   PubMed Web of Science ®Google Scholar